SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Aigner M)
 

Search: WFRF:(Aigner M) > Propionate attenuat...

  • Haghikia, A. (author)

Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2021-10-01
  • Oxford University Press (OUP),2022

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/314070
  • https://gup.ub.gu.se/publication/314070URI
  • https://doi.org/10.1093/eurheartj/ehab644DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:148848512URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Aims Atherosclerotic cardiovascular disease (ACVD) is a major cause of mortality and morbidity worldwide, and increased low-density lipoproteins (LDLs) play a critical role in development and progression of atherosclerosis. Here, we examined for the first time gut immunomodulatory effects of the microbiota-derived metabolite propionic acid (PA) on intestinal cholesterol metabolism. Methods and results Using both human and animal model studies, we demonstrate that treatment with PA reduces blood total and LDL cholesterol levels. In apolipoprotein E-/- (Apoe(-/-)) mice fed a high-fat diet (HFD), PA reduced intestinal cholesterol absorption and aortic atherosclerotic lesion area. Further, PA increased regulatory T-cell numbers and interleukin (IL)-10 levels in the intestinal microenvironment, which in turn suppressed the expression of Niemann-Pick C1-like 1 (Npc1l1), a major intestinal cholesterol transporter. Blockade of IL-10 receptor signalling attenuated the PA-related reduction in total and LDL cholesterol and augmented atherosclerotic lesion severity in the HFD-fed Apoe(-/-) mice. To translate these preclinical findings to humans, we conducted a randomized, double-blinded, placebo-controlled human study (clinical trial no. NCT03590496). Oral supplementation with 500 mg of PA twice daily over the course of 8 weeks significantly reduced LDL [-15.9 mg/dL (-8.1%) vs. -1.6 mg/dL (-0.5%), P = 0.016], total [-19.6 mg/dL (-7.3%) vs. -5.3 mg/dL (-1.7%), P = 0.014] and non-high-density lipoprotein cholesterol levels [PA vs. placebo: -18.9 mg/dL (-9.1%) vs. -0.6 mg/dL (-0.5%), P = 0.002] in subjects with elevated baseline LDL cholesterol levels. Conclusion Our findings reveal a novel immune-mediated pathway linking the gut microbiota-derived metabolite PA with intestinal Npc1l1 expression and cholesterol homeostasis. The results highlight the gut immune system as a potential therapeutic target to control dyslipidaemia that may introduce a new avenue for prevention of ACVDs.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Zimmermann, F. (author)
  • Schumann, P. (author)
  • Jasina, A. (author)
  • Roessler, J. (author)
  • Schmidt, D. (author)
  • Heinze, P. (author)
  • Kaisler, J. (author)
  • Nageswaran, V. (author)
  • Aigner, A. (author)
  • Ceglarek, U. (author)
  • Cineus, R. (author)
  • Hegazy, A. N. (author)
  • van der Vorst, E. P. C. (author)
  • Doring, Y. (author)
  • Strauch, C. M. (author)
  • Nemet, I. (author)
  • Tremaroli, Valentina,1978Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberg Laboratory,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xtreva (author)
  • Dwibedi, Chinmay,1987Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberglaboratoriet,Institute of Medicine, Department of Molecular and Clinical Medicine,Wallenberg Laboratory(Swepub:gu)xdwich (author)
  • Krankel, N. (author)
  • Leistner, D. M. (author)
  • Heimesaat, M. M. (author)
  • Bereswill, S. (author)
  • Rauch, G. (author)
  • Seeland, U. (author)
  • Soehnlein, O.Karolinska Institutet (author)
  • Muller, D. N. (author)
  • Gold, R. (author)
  • Bäckhed, Fredrik,1973Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberg Laboratory,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xbafre (author)
  • Hazen, S. L. (author)
  • Haghikia, A. (author)
  • Landmesser, U. (author)
  • Göteborgs universitetWallenberglaboratoriet (creator_code:org_t)

Related titles

  • In:European Heart Journal: Oxford University Press (OUP)43:6, s. 518-5330195-668X1522-9645

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view